Vivek Verma1, Adams Kusi Appiah2, Tim Lautenschlaeger3, Sebastian Adeberg4, Charles B Simone5, Chi Lin6. 1. Department of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA, USA. 2. Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE, USA. 3. Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN, USA. 4. Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. 5. Department of Radiation Oncology, University of Maryland Medical Center, Baltimore, MD, USA. 6. Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Abstract
BACKGROUND: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary national database. METHODS: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004-2013) receiving CT alone or CRT. Patients undergoing resection or not receiving CT were excluded, as were those with M1 disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT administration. Kaplan-Meier analysis evaluated overall survival (OS) between both groups. Cox proportional hazards modeling assessed variables associated with OS. RESULTS: In total, 2,842 patients were analyzed [n=666 (23%) CRT, n=2,176 (77%) CT]. CRT was less likely delivered at community centers, in more recent time periods (2009-2013), to older patients, and in certain geographic locations. Median OS in the CRT and CT groups were 13.6 vs. 10.5 months, respectively (P<0.001). On multivariate analysis, poorer OS was associated with age, male gender, increased comorbidities, treatment at a community center, and treatment at earlier time periods (2004-2008) (P<0.05 for all). Notably, receipt of CRT independently predicted for improved OS (P<0.001). CONCLUSIONS: As compared to CT alone, CRT was independently associated with improved survival in unresected IC. These findings support a randomized trial evaluating this question that is currently accruing.
BACKGROUND: Current guidelines recommend chemotherapy (CT) with or without radiotherapy (RT) for unresected intrahepatic cholangiocarcinoma (IC). Although there is currently lack of consensus, previous smaller studies have illustrated the efficacy of local therapy for this population. This investigation evaluated outcomes of chemoradiotherapy (CRT) versus CT alone in unresected IC using a large, contemporary national database. METHODS: The National Cancer Data Base (NCDB) was queried for primary IC cases (2004-2013) receiving CT alone or CRT. Patients undergoing resection or not receiving CT were excluded, as were those with M1 disease or unknown M classification. Logistic regression analysis ascertained factors associated with CRT administration. Kaplan-Meier analysis evaluated overall survival (OS) between both groups. Cox proportional hazards modeling assessed variables associated with OS. RESULTS: In total, 2,842 patients were analyzed [n=666 (23%) CRT, n=2,176 (77%) CT]. CRT was less likely delivered at community centers, in more recent time periods (2009-2013), to older patients, and in certain geographic locations. Median OS in the CRT and CT groups were 13.6 vs. 10.5 months, respectively (P<0.001). On multivariate analysis, poorer OS was associated with age, male gender, increased comorbidities, treatment at a community center, and treatment at earlier time periods (2004-2008) (P<0.05 for all). Notably, receipt of CRT independently predicted for improved OS (P<0.001). CONCLUSIONS: As compared to CT alone, CRT was independently associated with improved survival in unresected IC. These findings support a randomized trial evaluating this question that is currently accruing.
Authors: Vivek Verma; Christopher A Ahern; Christopher G Berlind; William D Lindsay; Sonam Sharma; Jacob Shabason; Melissa J Culligan; Surbhi Grover; Joseph S Friedberg; Charles B Simone Journal: J Thorac Oncol Date: 2017-08-24 Impact factor: 15.609
Authors: Waqar Haque; Vivek Verma; Mohamad Fakhreddine; Sandra Hatch; E Brian Butler; Bin S Teh Journal: Gynecol Oncol Date: 2016-10-23 Impact factor: 5.482
Authors: Matthew T McMillan; Eric Ojerholm; Vivek Verma; Kristin A Higgins; Sunil Singhal; Jarrod D Predina; Abigail T Berman; Surbhi Grover; Cliff G Robinson; Charles B Simone Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-11 Impact factor: 7.038
Authors: Regina V Tse; Maria Hawkins; Gina Lockwood; John J Kim; Bernard Cummings; Jennifer Knox; Morris Sherman; Laura A Dawson Journal: J Clin Oncol Date: 2008-01-02 Impact factor: 44.544
Authors: Kiri A Sandler; Darlene Veruttipong; Vatche G Agopian; Richard S Finn; Johnny C Hong; Fady M Kaldas; Saeed Sadeghi; Ronald W Busuttil; Percy Lee Journal: Adv Radiat Oncol Date: 2016-10-29
Authors: Brian De; Hop S Tran Cao; Jean-Nicolas Vauthey; Gohar S Manzar; Kelsey L Corrigan; Kanwal P S Raghav; Sunyoung S Lee; Ching-Wei D Tzeng; Bruce D Minsky; Grace L Smith; Emma B Holliday; Cullen M Taniguchi; Albert C Koong; Prajnan Das; Milind Javle; Ethan B Ludmir; Eugene J Koay Journal: Cancer Date: 2022-04-13 Impact factor: 6.921
Authors: Edward Christopher Dee; Morgan E Freret; Nora Horick; Ann C Raldow; Lipika Goyal; Andrew X Zhu; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jill N Allen; Cristina R Ferrone; Carlos Fernandez-Del Castillo; Kenneth K Tanabe; Lorraine C Drapek; Theodore S Hong; Motaz Qadan; Jennifer Y Wo Journal: Ann Surg Oncol Date: 2020-08-01 Impact factor: 5.344
Authors: Elaine Luterstein; Minsong Cao; James M Lamb; Ann Raldow; Daniel Low; Michael L Steinberg; Percy Lee Journal: Adv Radiat Oncol Date: 2019-10-10